EZH2 and breast cancer: Recently, it has been confirmed that a cyclopentenyl analog of 3-deazaadenosine, 3-deazaneplanocin A (DZNep), can reduce EZH2 expression in breast cancer cells and cause concomitant inhibition of H3K27me3 expression, which causes derepression of epigenetically silenced target genes [22].